Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737278 | 0.89 | PRCP (0.55) | PRCPHCRTR1HCRTR2LMNAALOX15 | |
| SCHEMBL12184052 | 0.79 | PRCP (0.42) | PRCPTP53NR1H2KLK7GPR119 | |
| SCHEMBL14749309 | 0.79 | PRCP (0.49) | PRCPNR1H2 | |
| SCHEMBL12183894 | 0.77 | PRCP (0.51) | PRCPTP53NR1H2GPR119LMNA | |
| SCHEMBL12184058 | 0.74 | PRCP (0.56) | PRCPTP53LMNAALOX15TSHR | |
| SCHEMBL12183923 | 0.74 | PRCP (0.56) | PRCPTP53LMNAALOX15TSHR | |
| SCHEMBL14701344 | 0.73 | PRCP (0.56) | PRCPTP53GPR119LMNAHPGDS | |
| SCHEMBL2597820 | 0.70 | KLK7 (0.41) | NR1H2KLK7 | |
| SCHEMBL12184081 | 0.70 | KMT2A (0.35) | TP53NR1H2KLK7LMNA | |
| SCHEMBL2597852 | 0.70 | KLK7 (0.41) | NR1H2KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885TP53 3882/4885ACHE 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.